AMaRC 18-02 - STUDY TITLE: A prospective Phase II study of Isatuximab Rescue for Inadequate response to Lenalidomide and Dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma (IRIL)
STATUS
Actively recruiting
CURRENT ENROLMENT
65 patients
Recruitment updated as of March 2023
STUDY DESIGN
Prospective, multicentre, open label trial, phase II study
CORRELATIVE STUDIES
Blood and bone marrow samples will be collected as part of the trial to assess the immunological, epigenetics and molecular profile
TRIAL PRINCIPAL INVESTIGATOR
Professor Hang Quach
TIME FRAME
2019 – 2023
PARTICIPANTS
Newly diagnosed multiple myeloma patients who are ineligible for high-dose chemotherapy and autologous stem cell transplant
SITE LOCATIONS
-
Alfred Hospital, VIC
-
Epworth Healthcare, VIC